

Vitiligo
Why is ruxolitinib uniquely suited to treat vitiligo compared to other JAK inhibitors?
Featuring Neal Bhatia, MD
Vitiligo
How does ruxolitinib compare to topical corticosteroids and topical calcineurin inhibitors for vitiligo?
Featuring Neal Bhatia, MD
Vitiligo
Does the efficacy of ruxolitinib for vitiligo vary across Fitzpatrick skin types?
Featuring Neal Bhatia, MD
Vitiligo
What rate of facial repigmentation was seen in clinical trials for ruxolitinib in patients with vitiligo?
Featuring Neal Bhatia, MD
Vitiligo
How frequently should dermatologists follow up with patients taking ruxolitinib for vitiligo?
Featuring Neal Bhatia, MD
Vitiligo
What strategies can dermatologists use to improve patient adherence to ruxolitinib for vitiligo?
Featuring Neal Bhatia, MD
Vitiligo
Is there a risk of systemic absorption with ruxolitinib for vitiligo?
Featuring Neal Bhatia, MD
Vitiligo
What are some therapies that are currently in the pipeline for the treatment of vitiligo?
Featuring Neal Bhatia, MD
Vitiligo
What are the emerging therapies or treatment modalities being investigated for vitiligo?
Featuring Neal Bhatia, MD
Vitiligo
How can dermatologists support patients in managing the psychological impacts of living with vitiligo?
Featuring Neal Bhatia, MD
Cutaneous Melanoma
What is the i31-SLNB algorithm, and how can it enhance SLNB guidance in melanoma management?
Featuring Harrison Nguyen, MD
Cutaneous Melanoma
What is the DecisionDx Melanoma test, and how does it work?
Featuring Harrison Nguyen, MD
Cutaneous Melanoma
What are the key clinical questions the DecisionDx Melanoma test helps answer?
Featuring Harrison Nguyen, MD
Cutaneous Melanoma
Is the DecisionDx test appropriate for all patients with melanoma, or are there specific eligibility criteria?
Featuring Harrison Nguyen, MD
Cutaneous Melanoma
How can the DecisionDx Melanoma test contribute to improved survival outcomes for patients?
Featuring Harrison Nguyen, MD
Cutaneous Melanoma
How does the DecisionDx Melanoma test compare to other GEP tests, such as the CP-GEP test, in clinical accuracy and utility?
Featuring Harrison Nguyen, MD
Cutaneous Melanoma
How can dermatologists explain the DecisionDx Melanoma test and its significance to their patients?
Featuring Harrison Nguyen, MD
Cutaneous Melanoma
What are the challenges in diagnosing melanoma in patients with skin of color, and how can they be addressed?
Featuring Harrison Nguyen, MD
Cutaneous Melanoma
How do you approach biopsying suspicious lesions, and what techniques yield the best diagnostic outcomes?
Featuring Harrison Nguyen, MD
Cutaneous Melanoma
What clinical and pathological features most significantly impact melanoma prognosis?
Featuring Harrison Nguyen, MD
Actinic Keratoses
With tirbanibulin ointment now approved for treating a larger surface area up to 100 cm², how does this improve treatment flexibility for patients and providers?
Featuring Theodore Rosen, MD
Actinic Keratoses
Can tirbanibulin ointment be safely and effectively used for actinic keratosis on the full face?
Featuring Theodore Rosen, MD
Actinic Keratoses
How does the safety of tirbanibulin ointment when treating larger surface areas compare to the safety observed in the original clinical trials?
Featuring Theodore Rosen, MD
Actinic Keratoses
Are skin reactions common with tirbanibulin ointment, and when do they typically peak?
Featuring Theodore Rosen, MD
24 of 719